This inventor holds 2 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignee: Chroma Therapeutics Limited. Active years: 2011-2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2012
Title: Michael Hugh Charlton: Innovator in IKK-beta Inhibitors
Introduction
Michael Hugh Charlton is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for IKK-beta serine-threonine protein kinase. His work is crucial for advancing treatments for autoimmune and inflammatory diseases.
Latest Patents
Charlton holds 2 patents related to his innovative compounds. His latest patents include inhibitors of IKK-beta serine-threonine protein kinase, which are designed to target IkB kinase (IKK) activity. These compounds are formulated to be effective in treating various autoimmune and inflammatory conditions.
Career Highlights
Charlton is currently associated with Chroma Therapeutics Limited, where he continues to push the boundaries of medical research and innovation. His expertise in the field has positioned him as a key player in the development of therapeutic solutions.
Collaborations
Some of his notable coworkers include Stephen John Davies and Simon Christopher Hirst. Their collaborative efforts contribute to the advancement of research and development in their respective fields.
Conclusion
Michael Hugh Charlton's work in developing IKK-beta inhibitors showcases his commitment to improving healthcare through innovative solutions. His contributions are vital for the ongoing fight against autoimmune and inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile